Thank you, Jeremy. Good afternoon, and thank you for joining us on our quarterly update call today. We issued our first fiscal year 2021 financial and operating results after the close of the market today, and I hope you’ve had a chance to look at them.
As we continue to drive forward in the pursuit of some normalcy in our daily lives, we at Enzo are extremely proud to have been part of the healthcare response to the COVID-19 pandemic. Despite the continuing challenges that were presented to our business by COVID-19, we delivered an extremely robust first quarter for 2021. The results were across multiple metrics of success. Both our revenue and accessions volume increased significantly over the prior quarter, reaching pre-pandemic levels and exceeding our initial estimates by $1.7 million, which we provided earlier. Total revenue was $28.7 million a 47% increase over the preceding fourth quarter of 2020. Demonstrating continued evidence of recovery and the subsequent positive impact from COVID-19 on our business operations.
We also saw continued margin improvement, leading to positive EBITDA of more than $1 million and positive earnings of approximately $0.01 per share.
Before elaborating further on the quarter, obviously we hope everyone has remained safe and healthy during the difficult and frustrating times. The health and safety of our employees has always been of extreme importance, and we greatly appreciate their contributions to keep our business running safely.
We have been very fortunate that the implemented measures to safeguard our employees have been successful, while allowing us to maintain full operations, so that we may continue to advance the important work we've been providing to our healthcare community. Even with the unprecedented challenges we faced this year, we were able to maintain our commitment to our core objectives; first, transforming into an integrated end to end diagnostic products and solutions company; second, building and investing in the infrastructure for growth; third, implementing efficiency measures to better bring in line or cost structure with the market needs; and fourth, building out our four key platforms and technologies to address enhanced value in the diagnostic sector. These objectives have helped us to further solidify Enzo's position as a comprehensive solutions provider in diagnostic products and services. Despite the unprecedented conditions of the COVID-19 pandemic, we have mobilized our operational resources to address the expanding needs of the market by servicing opportunities in new areas, including point of care and direct to consumer offerings.
While most companies and businesses during this period have remained partially closed if not fully closed, Enzo employees have not only manned the front lines but expanded our operational capacity to continuously support the testing needs of the market.
We are extremely proud to welcome Dr. Mary Tagliaferri and Dr. Ian Walters, two highly respected and experienced industry professionals to our board of directors, which now number four independent directors among the five on our board.
As executive clinical fellow and former Chief Medical Officer of Nektar, Dr. Tagliaferri brings deep business development, clinical research and development and global regulatory affairs skills to our board. Dr. Walters is CEO of Portage Biotech, and he has held executive positions at Bristol Myers Squibb and Millennium Pharmaceuticals. He's responsible for the development of more than 30 drugs, which lead to five new oncology drug approvals.
In addition to his business acumen, he will be instrumental in identifying new ways that Enzo can effectively support companion diagnostics, early drug discovery and liquid biopsy techniques. The addition of these two new directors significantly expands the operational and commercial expertise of our company's board, particularly concerning companion diagnostics and therapeutic opportunities.
During the quarter, we worked with our partners to provide COVID-19 testing services focused on our geographical region. This includes multiple universities, such as Stony Brook University, Farmingdale State University, as well as urgent care facilities, nursing homes and corporations. These were implemented to our schools and institutional testing, we call it our SIT programs, which we launched in June.
We are working with local government entities, helping them through this pandemic crisis as well.
We are focusing on building out these new relationships beyond COVID testing and transitioning them into long term opportunities, utilizing Enzo's full menu of products and services.
Our recent gotestmenow online portal is our first direct to consumer offering that brings quick convenient COVID testing to individuals overseeing by licensed physicians. Currently, we have now over 30 convenient locations in New York, New Jersey and Connecticut. It works as follows. A patient purchases the COVID-19 molecular or serological tests directly from the gotestmenow Web site and then goes to an Enzo clinical labs’ patient service center or pop up site for specimen collection. The results are delivered directly to the individual through our online portal. We plan to extend this online offering to sexually transmitted diseases and other types of testing. Furthermore, we are working on launching a home kit to enable self-testing for certain diseases.
We also recently announced the commercial launch of a small portable microplate reader for use with the company's immunoassay products. This affordable device enables Enzo to offer a complete solution to academic, CRO and other industrial customers. It is a compact plate reader that features an open design for quick plate loading and a USB connection. The personal 96 well format micro reader plate and machine can be used for a variety of applications, including a license, protein quantification assays, cell based assays and more. Ultimately, we hope it will provide new opportunities in points of care medicine.
On the research front, in a recently published book, titled In Situ Molecular Pathology and Co-Expression Analyses, Enzo loop RNA technology was expanded upon as a highly sensitive approach in the development of human papilloma virus probes. Enzo's loop RNA was compared against the market leader and demonstrated higher sensitivity. We believe this technology maybe extended beyond HPV for improved sensitivity with regards to other diagnostic testing.
We also have several innovations and product launches, including serological testing in a post vaccine environment that are in early days of adoption but we think will be a critical element of diagnostic testing in 2021. And we look forward to updating our investors on these initiatives as they come forward. I'd like to turn the call over to David, who will provide a financial update.